Merck & Co’s CEO has doubts over fast COVID-19 vaccine developmentMerck & Co’s CEO Kenneth Frazier has warned that the many COVID-19 vaccines under development are not guaranteed Share XMerck & Co’s CEO has doubts over fast COVID-19 vaccine developmenthttps://pharmaphorum.com/news/merck-cos-ceo-cast-doubts-about-fast-covid-19-vaccine-development/
Ex-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOAfter more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down Share XEx-Taris CEO Tony Kingsley claims tenure as Scholar Rock’s new CEOhttps://pharmaphorum.com/news/ex-taris-ceo-tony-kingsley-claims-tenure-as-scholar-rocks-new-ceo/
J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayThe FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 Share XJ&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayhttps://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/
Biogen and Eisai trial drug in asymptomatic Alzheimer’s diseaseBiogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but Share XBiogen and Eisai trial drug in asymptomatic Alzheimer’s diseasehttps://pharmaphorum.com/news/biogen-and-eisai-trial-drug-in-asymptomatic-alzheimers-disease/
Roche signs $1.7bn deal with Blueprint around cancer drug pralsetinibRoche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that Share XRoche signs $1.7bn deal with Blueprint around cancer drug pralsetinibhttps://pharmaphorum.com/news/roche-signs-1-7bn-deal-with-blueprint-around-cancer-drug-pralsetinib/
NHS Trust use of data analytics spikes amid COVID-19 crisisAs the first wave of the coronavirus pandemic swept through the UK, NHS Trusts responded by adopting data Share XNHS Trust use of data analytics spikes amid COVID-19 crisishttps://pharmaphorum.com/news/nhs-trust-use-of-data-analytics-spikes-amid-covid-19-crisis/
UK firms plan early-warning detector for COVID-19 in wastewaterSewage monitoring is being trialled as a way to spot new outbreaks of coronavirus, and three UK companies Share XUK firms plan early-warning detector for COVID-19 in wastewaterhttps://pharmaphorum.com/news/uk-firms-plan-early-warning-detector-for-covid-19-in-wastewater/
FDA to fast track development of two COVID-19 vaccines from Pfizer and BioNTechTwo of Pfizer and BioNTech’s potential COVID-19 vaccines have been granted Fast Track status by the FDA, a Share XFDA to fast track development of two COVID-19 vaccines from Pfizer and BioNTechhttps://pharmaphorum.com/news/fda-to-fast-track-development-of-two-covid-19-vaccines-from-pfizer-and-biontech/
Tom Richards joins 21GRAMS as co-global chief creative officerW2O advertising and marketing agency 21GRAMS has appointed Tom Richards as its co-global chief creative officer. He joins Share XTom Richards joins 21GRAMS as co-global chief creative officerhttps://pharmaphorum.com/news/tom-richards-w2o-21grams/
